Search results
Results from the WOW.Com Content Network
Schwartz notes that the Harrington–Hollingsworth experiment was a turning point in the understanding of ITP's pathophysiology: The Harrington–Hollingsworth experiment changed the meaning of the "I" in ITP from idiopathic to immune, but "immune" in this case means "autoimmune," because the antibodies bind to and cause the destruction of the patient's own platelets.
Approximately 10% of newborns affected by ITP will have platelet counts <50,000/uL and 1% to 2% will have a risk of intracerebral hemorrhage, comparable to that of infants with neonatal alloimmune thrombocytopenia (NAIT). [64] [65] No lab test can reliably predict if neonatal thrombocytopenia will occur.
Pseudothrombocytopenia (PTCP) or spurious thrombocytopenia is an in-vitro sampling problem which may mislead the diagnosis towards the more critical condition of thrombocytopenia. The phenomenon may occur when the anticoagulant used while testing the blood sample causes clumping of platelets which mimics a low platelet count. [ 1 ]
Platelet count begins to rise after 2 to 5 days' abstinence from alcohol. The condition is generally benign, and clinically significant hemorrhage is rare. [citation needed] In severe thrombocytopenia, a bone marrow study can determine the number, size, and maturity of the megakaryocytes. This information may identify ineffective platelet ...
High platelet counts can occur in patients with polycythemia vera (high red blood cell counts), and is an additional risk factor for complications. [ citation needed ] A very small number of people report symptoms of erythromelalgia , a burning sensation and redness of the extremities that resolves with cooling, or aspirin or both.
Neonatal alloimmune thrombocytopenia (NAITP, NAIT, NATP or NAT) is a disease that affects babies in which the platelet count is decreased because the mother's immune system attacks her fetus' or newborn's platelets. A low platelet count increases the risk of bleeding in the fetus and newborn.
Multiplate multiple electrode aggregometry (MEA) is a test of platelet function in whole blood. [ 1 ] [ 2 ] The test can be used to diagnose platelet disorders, [ 3 ] [ 4 ] [ 5 ] monitor antiplatelet therapy, [ 6 ] and is also investigated as a potential predictor of transfusion requirements and bleeding risk in cardiac surgery.
Consensus statements differ from medical guidelines, another form of state-of-the-science public statements. According to the NIH, "Consensus statements synthesize new information, largely from recent or ongoing medical research , that has implications for reevaluation of routine medical practices.